アブストラクト
Japanese
Title | 脊髄障害性疼痛と神経再生医療 |
---|---|
Subtitle | 総説 |
Authors | 山下敏彦, 福士龍之介, 廣田亮介, 押切勉, 栗原康太 |
Authors (kana) | |
Organization | 札幌医科大学医学部 整形外科 |
Journal | 日本運動器疼痛学会誌 |
Volume | 13 |
Number | 1 |
Page | 7-12 |
Year/Month | 2021 / |
Article | 報告 |
Publisher | 日本運動器疼痛学会 |
Abstract | 要旨: 脊髄損傷症例の約2/3で疼痛を伴い, しばしば難治性となる. われわれは2019年5月より, 保険診療下に自己骨髄間葉系幹細胞(MSC)の静脈内投与による脊髄損傷治療を開始している. MSC投与を行った症例の多くで良好な機能回復が得られた. また多くの症例でMSC投与後に疼痛(VAS)の低下を認めた. MSCの静脈内投与は, 脊髄損傷に伴う神経障害性疼痛などの慢性疼痛に対する有効な治療法となる可能性がある. |
Practice | 臨床医学:外科系 |
Keywords | 脊髄損傷(Spinal cord injury), 間葉系幹細胞(Mesenchymal stem cell), 神経障害性疼痛(Neuropathic pain) |
English
Title | Regenerative medicine for neuropathic pain caused by spinal cord injury |
---|---|
Subtitle | |
Authors | Toshihiko Yamashita, Ryunosuke Fukushi, Ryosuke Hirota, Tsutomu Oshigiri, Kota Kurihara |
Authors (kana) | |
Organization | Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine |
Journal | Journal of Musculoskeletal Pain Research |
Volume | 13 |
Number | 1 |
Page | 7-12 |
Year/Month | 2021 / |
Article | Report |
Publisher | Japanese Association for the Study of Musculoskeletal Pain |
Abstract | Abstract: Around two-thirds of spinal cord injury patients suffer from chronic pain that often becomes interactive. We have provided treatment for spinal cord injury patients using the intravenous administration of autologous bone marrow mesenchymal stem cells (MSC) under the National Health Insurance scheme since May, 2019. A majority of patients showed functional recovery after MSC administration. Visual analogue scale (VAS) scores for pain in patients were also found to decrease after MSC administration. Intravenous MSC transplantation may be an effective treatment for neuropathic pain caused by spinal cord injury. |
Practice | Clinical surgery |
Keywords | Spinal cord injury, Mesenchymal stem cell, Neuropathic pain |
- 全文ダウンロード: 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Wringley PJ, Siddall PJ. Pain following spinal cord injury. In:McMahon SB, Koltzenburg M, Tracey I, et al. ed. Wall & Melzack's TEXTBOOK OF PAIN, 6th Edition, Elsevier, Amsterdam, 2013:978-89.
- 2) Siddall PL, McClelland JM, Rutkowski SB, et al. A longitudinal study of the revalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003;103:249-57.
- 3) Sasaki M, Redtke C, Tan AM, et al. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 2009;29:14932-41.
- 4) Osaka M, Honmou O, Murakami T, et al. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res 2010;1343:226-35.
- 5) 山下敏彦. 脊髄損傷に対する自家骨髄間葉系幹細胞の静脈内投与による細胞療法. 日脊障医誌 2018;31::12-5.
残りの10件を表示する
- 6) 山下敏彦, 佐々木雄一, 本望修. 脊髄損傷に対する自己骨髄間葉系幹細胞治療とリハビリテーション. Journal of Clinical Rehabilitation 2020;29:473-9.
- 7) Brini AT, Amodeo G, Ferreira LM, et al. Therapeutic effect of human adiposederived stem cells and their secretome in experimental diabetic pain. Sci Rep 2017;7:9904.
- 8) Sun Y, Tian Y, Li H, et al. Antinociceptive effect of intrathecal injection of genetically engineered human bone marrow stem cells expressing the human proenkephalin gene in a rat model of bone cancer pain. Pain Res Manag 2017;2017:7346103.
- 9) Khatab S, van Osch GJ, Kops N, et al. Mesenchymal stem cell secretome reduces pain and prevents cartilage damage in a murine osteoarthritis model. Eur Cell Mater 2018;36:218-30.
- 10) Lindsay SL, Toft A, Griffin J, et al. Human olfactory mesenchymal stromal cell transplants promote remyelination and earlier improvement in gait co-ordination after spinal cord injury. Glia 2017;65:639-56.
- 11) Oshigiri T, Sasaki T, Sasaki M, et al. Intravenous infusion of mesenchymal stem cells alters motor cortex gene expression in a rat model of acute spinal cord injury. J Neurotrauma 2019;36:411-20.
- 12) Chahal J, Gomez-Aristizabal A, Shestopaloff K, et al. Bone marrow mesenchymal stromal cell treatment in patients with osteoarthritis results in overall improvement in pain and symptoms and reduces synovial inflammation. Stem Cells Transl Med 2019;8:746-57.
- 13) Lee WS, Kim HJ, Kim KI, et al. Intraarticular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis:A phase IIb, randomized, placebo-controlled clinical trial. Stem Cells Transl Med 2019;8:504-11.
- 14) Matas J, Orrego M, Amenabar D, et al. Umbilical cord-derived mesenchymal stromal cells(MSCs) for knee osteoarthritis:repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II Trial. Stem Cells Transl Med 2019;8:215-24.
- 15) Vaquero J, Zurita M, Rico MA, et al. Intrathecal administration of autologous bone marrow stromal cells improves neuro pathic pain in patients with spinal cord injury. Neurosci Lett 2018;670:14-8.